As shown in Figure 1A–C, anti-PD-1 antibody combined with cabozantinib plus chidamide-k30 regimen more effectively inhibited tumor growth than anti-PD-1 antibody combined with cabozantinib regimens, as expected. The gene discussed is PDCD1; the disease is neoplasm.